Research Analysts Issue Forecasts for Valneva Q3 Earnings

Key Points

• HC Wainwright raised Valneva’s Q3 2026 EPS forecast to a loss of $0.18 per share from a projected loss of $0.21. The firm expects losses of $1.04 per share for FY2026 before forecasting profits from FY2027 onward.
• Valneva reported a Q2 loss of $0.40 per share, missing consensus estimates by $0.21, while revenue of $39.37 million fell short of the $44.17 million estimate.
• Analyst sentiment remains mixed, with four Buy ratings and two Sell ratings, resulting in a consensus “Hold” rating and an average price target of $11.98 versus the stock’s $7.06 opening price.

Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2026 earnings per share estimates for Valneva in a research report issued on Friday, August 14th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.18) per share for the quarter, up from their previous forecast of ($0.21). The consensus estimate for Valneva's current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Valneva's Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at $1.80 EPS, FY2028 earnings at $2.12 EPS, FY2029 earnings at $2.26 EPS and FY2030 earnings at $3.94 EPS.

VALN has been the subject of several other reports. TD Cowen began coverage on Valneva in a research note on Tuesday, August 11th. They issued a "buy" rating and a $12.00 target price for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Valneva in a report on Thursday, June 18th. Wall Street Zen upgraded Valneva from a "strong sell" rating to a "sell" rating in a research report on Monday, June 1st. Finally, The Goldman Sachs Group cut Valneva from a "neutral" rating to a "sell" rating and set a $4.90 price objective for the company. in a report on Wednesday, April 22nd. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Valneva presently has an average rating of "Hold" and an average target price of $11.98.

Valneva Stock Performance

Shares of Valneva stock opened at $7.06 on Tuesday. The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69. The firm has a 50 day simple moving average of $5.28 and a 200 day simple moving average of $6.89. Valneva has a fifty-two week low of $4.75 and a fifty-two week high of $12.25. The firm has a market cap of $669.92 million, a P/E ratio of -3.35 and a beta of 1.77.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The company had revenue of $39.37 million during the quarter, compared to analyst estimates of $44.17 million.

Hedge Funds Weigh In On Valneva

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VALN. China Universal Asset Management Co. Ltd. acquired a new stake in Valneva in the 4th quarter valued at $44,000. JPMorgan Chase & Co. bought a new stake in shares of Valneva during the third quarter worth approximately $124,000. XTX Topco Ltd acquired a new stake in shares of Valneva during the fourth quarter worth $94,000. Finally, Marex Group plc acquired a new position in shares of Valneva in the second quarter valued at about $64,000. Institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva's research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source